China Mesalazine Market, by Route of Administration (Oral and Rectal), by Application (Ulcerative Colitis, Crohn's Disease, and Inflammatory Bowel Disease), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) is estimated to be valued at US$ 51.6 Million in 2022 and is expected to exhibit a CAGR of 3.1% during the forecast period (2022-2030), as highlighted in a new report published by Coherent Market Insights.
Increasing research studies in the country is expected to drive China mesalazine market growth over the forecast period. For instance, according to a research study performed by Tianjin University of Traditional Chinese Medicine, China in March 2020, mesalazine and probiotics were effective and safe treatments for ulcerative colitis. The study suggested that mesalazine and probiotics did not increase the risk of drug use and had high safety.
China Mesalazine Market – Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and consequent lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
However, the COVID-19 pandemic had a positive impact on China mesalazine market. Mesalazine or 5-aminosalicylic acid is a drug, which is used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Since the first outbreak of coronavirus (COVID-19) in China in December 2019, the infection has grown to become the most serious medical problem. High mortality among patients with numerous overcrowding in intensive care units was an important contributor that exacerbated the COVID-19 disease's impact, and as a result, increased the strain on healthcare systems. Patients with inflammatory bowel disease (IBD) were more vulnerable to opportunistic infections (OIs); as a result, the use of mesalazine increased for the treatment of inflammatory bowel diseases such as ulcerative colitis, etc. According to the data published in National Center for Biotechnology Information in November 2020, throughout the pandemic, the Surveillance Epidemiology of Coronavirus under Research Exclusion (SECURE-IBD) international registry has helped clinicians and patients in China to better understand outcomes of COVID-19 in patients with IBD. In January 2022, 7,038 cases of COVID-19 from 74 countries had been reported to determine the impact of IBD treatment regimens on outcomes of COVID-19, including hospitalization and severe COVID-19.
China Mesalazine Market: Key Developments
Initiating research and development activities such as clinical trials for the treatment of Crohn’s disease is anticipated to boost the market growth over the forecast period. For instance, in January 2022, Sixth Affiliated Hospital, Sun Yat-sen University, China initiated the randomized controlled clinical study of the drug mesalazine to evaluate the efficacy of mesalazine combined with biologics in the treatment of moderate to severe conditions of Crohn’s disease.